Alteration of lineage-specific transcriptional programs for hematopoiesis causes differentiation block and promotes leukemia development. Here, we show that AML1/ETO, the most common translocation fusion product in acute myeloid leukemia (AML), counteracts the activity of retinoic acid (RA), a transcriptional regulator of myelopoiesis. AML1/ETO participates in a protein complex with the RA receptor alpha (RARα) at RA regulatory regions on RARβ2, which is a key RA target gene mediating RA activity/resistance in cells. At these sites, AML1/ETO recruits histone deacetylase, DNA methyltransferase, and DNA-methyl-CpG binding activities that promote a repressed chromatin conformation. The link among AML1/ETO, heterochromatic RARβ2 repression, RA resistance, and myeloid differentiation block is indicated by the ability of either siRNA-AML1/ETO or the DNA methylation inhibitor 5-azacytidine to revert these epigenetic alterations and to restore RA differentiation response in AML1/ETO blasts. Finally, RARβ2 is commonly silenced by hypermethylation in primary AML blasts but not in normal hematopoietic precursors, thus suggesting a role for the epigenetic repression of the RA signaling pathway in myeloid leukemogenesis. © 2007 by The American Society of Hematology.

Heterochromatic gene repression of the retinoic acid pathway in acute myeloid leukemia / Fazi, Francesco; Zardo, Giuseppe; V., Gelmetti; L., Travaglini; A., Ciolfi; L., Di Croce; Rosa, Alessandro; Bozzoni, Irene; F., Grignani; F., Lo Coco; P. G., Pelicci; Nervi, Clara. - In: BLOOD. - ISSN 0006-4971. - STAMPA. - 109:10(2007), pp. 4432-4440. [10.1182/blood-2006-09-045781]

Heterochromatic gene repression of the retinoic acid pathway in acute myeloid leukemia

FAZI, Francesco;ZARDO, GIUSEPPE;ROSA, ALESSANDRO;BOZZONI, Irene;NERVI, Clara
2007

Abstract

Alteration of lineage-specific transcriptional programs for hematopoiesis causes differentiation block and promotes leukemia development. Here, we show that AML1/ETO, the most common translocation fusion product in acute myeloid leukemia (AML), counteracts the activity of retinoic acid (RA), a transcriptional regulator of myelopoiesis. AML1/ETO participates in a protein complex with the RA receptor alpha (RARα) at RA regulatory regions on RARβ2, which is a key RA target gene mediating RA activity/resistance in cells. At these sites, AML1/ETO recruits histone deacetylase, DNA methyltransferase, and DNA-methyl-CpG binding activities that promote a repressed chromatin conformation. The link among AML1/ETO, heterochromatic RARβ2 repression, RA resistance, and myeloid differentiation block is indicated by the ability of either siRNA-AML1/ETO or the DNA methylation inhibitor 5-azacytidine to revert these epigenetic alterations and to restore RA differentiation response in AML1/ETO blasts. Finally, RARβ2 is commonly silenced by hypermethylation in primary AML blasts but not in normal hematopoietic precursors, thus suggesting a role for the epigenetic repression of the RA signaling pathway in myeloid leukemogenesis. © 2007 by The American Society of Hematology.
2007
01 Pubblicazione su rivista::01a Articolo in rivista
Heterochromatic gene repression of the retinoic acid pathway in acute myeloid leukemia / Fazi, Francesco; Zardo, Giuseppe; V., Gelmetti; L., Travaglini; A., Ciolfi; L., Di Croce; Rosa, Alessandro; Bozzoni, Irene; F., Grignani; F., Lo Coco; P. G., Pelicci; Nervi, Clara. - In: BLOOD. - ISSN 0006-4971. - STAMPA. - 109:10(2007), pp. 4432-4440. [10.1182/blood-2006-09-045781]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/358943
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 29
  • Scopus 79
  • ???jsp.display-item.citation.isi??? 70
social impact